Regeneron Pharmaceuticals, Inc.

Giovanni Coppola

Aris I Baras

Goncalo Abecasis

Kavita Praveen

Lauren Gurski

Carmelo Romano

Manuel Allen Revez Ferreira

Tanya Teslovich Dostal

Claudia Schurmann

Ying Hu

Meghan Drummond Samuelson

Ann Ligocki

Arden Moscati

Gaurang Patel

Sahar Gelfman

Eli A Stahl

Giusy Della Gatta

Santiago Mendez Huergo

Tave Van Zyl

Jonathan Weyne

Jack A Kosmicki

Trikaldarshi Persaud

The present disclosure provides methods of treating subjects having an immune disorder by administering to the subject a therapeutically effective amount of an Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) inhibitor in combination with an HLA-A29 or HLA-B27 inhibitory nucleic acid molecule.

Materials and methods of treating MHC-I-opathy risk haplotypes

The present disclosure provides methods of treating subjects having hearing loss, methods of identifying subjects having an increased risk of developing hearing loss, and methods of detecting Kelch Domain Containing 7B (KLHDC7B) variant nucleic acid molecules and variant polypeptides.

Kelch domain containing 7B (KLHDC7B) variants and uses thereof

The present disclosure provides methods of treating subjects having uveitis, and methods of identifying subjects having an increased risk of developing uveitis.

Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (ERAP1) inhibitors

The present disclosure provides methods of treating subjects having inflammation with an Angiopoietin-Like 7 (ANGPTL7) inhibitor and a glucocorticoid, methods of decreasing glucocorticoid-induced ophthalmic conditions in subjects, and methods of identifying subjects having an increased risk of developing glucocorticoid-induced ophthalmic conditions.

Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (ANGPTL7) inhibitors

The present disclosure provides methods of treating patients having an ophthalmic condition, methods of identifying subjects having an increased risk of developing an ophthalmic condition, methods of detecting human angiopoietin like 7 (ANGPTL7) variant nucleic acid molecules and variant polypeptides, and ANGPTL7 variant nucleic acid molecules and variant polypeptides.

Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors

The present disclosure provides methods of treating patients having an ophthalmic condition, methods of identifying subjects having an increased risk of developing an ophthalmic condition, methods of detecting human Son of Sevenless 2 (SOS2) variant nucleic acid molecules and variant polypeptides.

Treatment of ophthalmic conditions with son of Sevenless 2 (SOS2) inhibitors

Growing community of inventors

Tarrytown, NY, United States of America

Giovanni Coppola